DNA-PKcs (PRKDC) Protein

Overview

DNA-dependent protein kinase catalytic subunit (DNA-PKcs) is a serine/threonine protein kinase that plays a critical role in the cellular DNA damage response (DDR). As the catalytic subunit of the DNA-dependent protein kinase (DNA-PK) complex, DNA-PKcs forms a heterotrimeric holoenzyme with the Ku70/Ku80 heterodimer to mediate non-homologous end joining (NHEJ), the predominant pathway for repairing double-strand breaks (DSBs) in mammalian cells.

Beyond its well-established function in DNA repair, DNA-PKcs has emerged as a key regulator of neuronal viability and stress response. Neurons are particularly vulnerable to DNA damage due to their post-mitotic state and high metabolic activity, which generates significant oxidative stress. Accumulating evidence links DNA-PKcs dysfunction to the pathogenesis of Alzheimer’s disease (AD), Parkinson’s disease (PD), and other neurodegenerative conditions. ^{1The DNA damage response in neurodegeneration2005 · Nat Rev Neurosci · PMID 15959463Open reference}

Recent research has revealed that DNA-PKcs participates in additional cellular processes beyond DNA repair, including:

• Regulation of telomere length and stability

• V(D)J recombination in lymphocyte development

• Transcriptional regulation through chromatin remodeling

• Mitochondrial function and cellular metabolism

• Tau phosphorylation in AD pathogenesis

• Stress granule formation in response to cellular stress

Structure and Mechanism

Domain Architecture

DNA-PKcs is one of the largest known protein kinases, comprising 4,127 amino acids with a molecular weight of approximately 469 kDa. The protein contains multiple functional domains:

N-terminal Regulatory Domain: The N-terminal region contains the catalytic subunit’s regulatory components:

• Three HEAT repeats that mediate protein-protein interactions

• A Ku-binding domain that interacts with the Ku70/Ku80 heterodimer

• A leucine-rich repeat (LRR) region involved in DNA binding

• A C-terminal region containing the kinase domain

Kinase Domain (C-terminal): The C-terminal ~380 amino acids constitute the serine/threonine protein kinase domain:

• Belongs to the PI3/PI4-related protein kinase family

• Kinase activity is DNA-dependent, requiring DNA binding for activation

• Contains the activation loop and P+1 loop typical of AGC family kinases

• Autophosphorylation at multiple sites (Ser2056, Thr2609, Ser2056) regulates activity

DNA-Binding Domain: DNA-PKcs contains specialized domains for DNA binding:

• N-terminal DNA-binding domain

• Ku heterodimer serves as DNA damage sensor

• DNA binding induces conformational changes activating kinase

Activation Mechanism

DNA-PKcs activation follows a well-characterized pathway:

1. DNA damage detection: DSBs are sensed by the Ku70/Ku80 heterodimer, which rapidly binds to DNA ends

2. Recruitment of DNA-PKcs: DNA-PKcs is recruited to the DNA-Ku complex through protein-protein interactions

3. Conformational activation: DNA binding induces a conformational change in DNA-PKcs, exposing the kinase domain

4. Autophosphorylation: DNA-PKcs undergoes autophosphorylation at multiple sites, stabilizing the active conformation

5. Substrate phosphorylation: Activated DNA-PKcs phosphorylates downstream targets involved in DNA repair, transcription, and cell survival

Normal Physiological Function

DNA Double-Strand Break Repair (NHEJ)

DNA-PKcs is the central effector kinase in the classical non-homologous end joining (c-NHEJ) pathway:

Core NHEJ Pathway:

• Ku70/Ku80 heterodimer binds DNA ends (within seconds of damage)

• DNA-PKcs recruited and activated by DNA-Ku complex

• DNA-PKcs phosphorylates downstream effectors (XRCC4, Ligase IV, XLF, Artemis)

• DNA ends processed and ligated by Ligase IV/XRCC4/XLF complex

• DNA-PKcs activity regulated by autophosphorylation (Ser2056, Thr2609)

Alternative End Joining (alt-NHEJ): When c-NHEJ is compromised, cells resort to alternative pathways:

• Microhomology-mediated end joining (MMEJ)

• DNA-PKcs-independent pathways can partially compensate

V(D)J Recombination

In developing lymphocytes, DNA-PKcs is essential for V(D)J recombination:

• Required for antigen receptor gene rearrangement

• Mutations in PRKDC cause severe combined immunodeficiency (SCID) in mice and humans

• Defective V(D)J recombination leads to immunodeficiency

Transcriptional Regulation

DNA-PKcs modulates gene expression through:

Chromatin Remodeling:

• Phosphorylates histone H2AX (forming γ-H2AX)

• Recruits chromatin remodeling complexes

• Facilitates transcriptional reprogramming after DNA damage

RNA Polymerase II Regulation:

• Phosphorylates RNA Pol II C-terminal domain

• Coordinates transcription with DNA repair

• Regulates expression of stress response genes

Telomere Maintenance

DNA-PKcs contributes to telomere stability:

• Localizes to telomeres through Ku interaction

• Prevents telomere end-to-end fusions

• Maintains telomere length in proliferating cells

Neuronal Function

In post-mitotic neurons, DNA-PKcs has specialized functions:

DNA Damage Repair:

• Neurons rely on NHEJ for DSB repair (no homologous recombination)

• DNA-PKcs is the primary DSB repair kinase in neurons

• Critical for neuronal survival given high oxidative stress

Stress Response:

• Regulates stress-activated signaling pathways

• Participates in stress granule formation

• Modulates neuronal responses to oxidative stress

Metabolic Regulation:

• Links metabolic status to DNA integrity

• DNA-PKcs activity affected by cellular energy state

• May influence neuronal plasticity

Role in Neurodegenerative Diseases

Alzheimer’s Disease

DNA-PKcs has emerged as a significant player in AD pathogenesis:

DNA Damage Accumulation: AD brains show elevated levels of DNA damage, including DSBs:

• Oxidative stress generates persistent DNA damage in neurons

• DNA repair capacity declines with age and in AD

• DNA-PKcs activity is reduced in AD brains ^{2DNA-PK deficiency in Alzheimer's disease2007 · J Neurosci Res · PMID 17214460Open reference}

• Accumulated DNA damage contributes to neuronal dysfunction and death

Tau Pathology: A critical discovery links DNA-PKcs to tau phosphorylation:

• DNA-PKcs directly phosphorylates tau at multiple sites ^{3DNA-PK and tau pathology in Alzheimer's disease2017 · Nat Neurosci · PMID 28556847Open reference}

• Thr262, Ser356, and Ser396 are DNA-PKcs phosphorylation sites

• Hyperphosphorylated tau is a hallmark of AD neurofibrillary tangles

• DNA-PKcs activity is elevated in AD brains, promoting tau pathology ^{4DNA-PKcs-mediated tau phosphorylation in Alzheimer's disease2023 · J Biol Chem · PMID 36740241Open reference}

• DNA-PKcs inhibition reduces tau phosphorylation in cellular models

Amyloid-Beta Effects:

• Aβ exposure increases neuronal DNA damage

• DNA-PKcs activation is part of the Aβ-induced stress response

• DNA-PKcs may link Aβ toxicity to downstream tau pathology

Therapeutic Implications:

• DNA-PKcs inhibitors have shown neuroprotective effects in AD models

• Reducing DNA-PKcs activity decreases tau phosphorylation

• However, completely inhibiting DNA repair may have adverse effects

Parkinson’s Disease

DNA-PKcs involvement in PD has been increasingly recognized:

Dopaminergic Neuron Vulnerability:

• Dopaminergic neurons in the substantia nigra are particularly vulnerable

• These neurons accumulate DNA damage with aging

• DNA-PKcs activity may be dysregulated in PD ^{5DNA damage response in Parkinson's disease models2023 · Neurobiol Dis · PMID 37179235Open reference}

Alpha-Synuclein Interaction:

• DNA-PKcs may be affected by α-synuclein pathology

• Lewy bodies contain DNA damage response proteins

• DNA-PKcs may contribute to α-synuclein-induced toxicity

Mitochondrial DNA Damage:

• PD is associated with mitochondrial dysfunction

• Mitochondrial DNA (mtDNA) damage accumulates in PD

• DNA-PKcs may participate in mtDNA repair pathways

• Impaired mtDNA repair contributes to energy failure

LRK2 Interaction:

• LRRK2 mutations are a major cause of familial PD

• DNA-PKcs and LRRK2 may have overlapping functions

• Both kinases are involved in neuronal stress response

Other Neurodegenerative Conditions

Amyotrophic Lateral Sclerosis (ALS): Motor neurons are particularly vulnerable to DNA damage due to their large size, high metabolic demand, and dependence on efficient DNA repair mechanisms:

• Motor neurons accumulate DNA damage in ALS

• DNA-PKcs activity is altered in ALS models

• DNA repair deficiency may contribute to motor neuron death

• Sporadic and familial ALS show evidence of DNA repair impairment

• DNA-PKcs dysfunction may exacerbate motor neuron vulnerability

Huntington’s Disease (HD): The polyglutamine expansion in mutant huntingtin protein promotes genomic instability:

• Mutant huntingtin promotes DNA damage through multiple mechanisms

• DNA-PKcs dysregulation in HD models

• DNA repair deficits are an early event in HD pathogenesis

• DNA-PKcs activity may be impaired in HD patient tissues

• Enhancing DNA repair capacity is a therapeutic strategy under investigation

Multiple Sclerosis: Oligodendrocytes are the myelin-producing cells that are targeted in MS:

• DNA damage accumulates in oligodendrocytes in MS

• DNA-PKcs may be involved in demyelination processes

• Myelin repair requires DNA repair capacity

• DNA-PKcs dysfunction may impair oligodendrocyte precursor differentiation

Ataxia-Telangiectasia: This autosomal recessive disorder is caused by ATM mutations:

• ATM deficiency causes progressive neurodegeneration

• DNA-PKcs can partially compensate for ATM loss

• Combined deficiencies cause severe neurological phenotypes

• ATM and DNA-PKcs have overlapping functions in the DNA damage response

Signaling Pathway Diagram

flowchart TD
    A["DNA Double-Strand<br/>Break"] --> B["Ku70/Ku80<br/>Binding"]
    B --> C["DNA-PKcs<br/>Recruitment"]
    C --> D["DNA-PKcs<br/>Activation"]
    D --> E["Autophosphorylation<br/>Ser2056, Thr2609"]
    E --> F["Downstream<br/>Signaling"]

    F --> G["NHEJ Repair<br/>Pathway"]
    F --> H["Transcription<br/>Regulation"]
    F --> I["Cell Cycle<br/>Checkpoints"]
    F --> J["Apoptosis<br/>Regulation"]

    G --> K["XRCC4/Ligase IV<br/>Recruitment"]
    G --> L["DNA End<br/>Ligation"]
    K --> M["DNA Damage<br/>Resolution"]

    H --> N["RNA Pol II<br/>Phosphorylation"]
    H --> O["Chromatin<br/>Remodeling"]
    N --> P["Stress Response<br/>Gene Expression"]

    I --> Q["Cell Cycle<br/>Arrest"]
    I --> R["DNA Repair<br/>Checkpoint"]

    J --> S["Survival<br/>Signaling"]
    J --> T["Apoptotic<br/>Pathways"]

    U["AD Pathology"] --> V["DNA Damage<br/>Accumulation"]
    U --> W["Tau<br/>Hyperphosphorylation"]
    V --> X["DNA-PKcs<br/>Dysregulation"]
    W --> X
    X --> Y["Neuronal<br/>Dysfunction"]
    X --> Z["Tau Pathology<br/>Progression"]

    AA["PD Pathology"] --> AB["Oxidative Stress"]
    AA --> AC["Mitochondrial<br/>Dysfunction"]
    AB --> AD["DNA Damage<br/>Accumulation"]
    AC --> AD
    AD --> AE["DNA-PKcs<br/>Activation"]
    AE --> AF["Dopaminergic<br/>Neuron Death"]

Therapeutic Implications

DNA-PKcs as a Therapeutic Target

Targeting DNA-PKcs in neurodegeneration presents both opportunities and challenges:

Inhibitor Development: Several DNA-PKcs inhibitors have been developed:

• NU7441: Potent and selective DNA-PKcs inhibitor

• KU-0060648: Dual PI3K/DNA-PKcs inhibitor

• CC-115: DNA-PKcs inhibitor in clinical trials for cancer

• M3814 (Peposertib): Clinical-stage DNA-PKcs inhibitor

Neuroprotective Strategies:

• Low-dose DNA-PKcs inhibition may reduce tau pathology

• Temporary inhibition during acute stress phases

• Combination approaches with other therapeutic agents

Challenges and Considerations

Dual Nature of DNA-PKcs Inhibition:

• Beneficial: Reduces tau phosphorylation, limits DNA damage signaling

• Risky: Impairs DNA repair, potentially increasing genomic instability

Therapeutic Window:

• Identifying optimal dosing for neuroprotection

• Balancing DNA repair capacity with pathological signaling

• Tissue-specific targeting (CNS vs. peripheral)

Alternative Approaches:

• Targeting downstream effectors rather than DNA-PKcs directly

• Modulating DNA-PKcs activity through allosteric mechanisms

• Enhancing DNA repair capacity through other pathways

Current Research Directions

Preclinical Studies:

• DNA-PKcs inhibitors in AD mouse models show reduced tau pathology

• Genetic knockdown of DNA-PKcs improves cognitive function in AD models

• Combination therapy with Aβ-targeting agents

Clinical Translation:

• Blood-brain barrier penetration is a major challenge

• Prodrug strategies for CNS delivery

• Biomarker development for patient selection

Interacting Partners

Research Highlights

Key Findings

1. Meek et al. (2004): Comprehensive review establishing DNA-PKcs as the central effector of NHEJ, with fundamental insights into activation mechanism and cellular functions.

2. Bhattacharyya et al. (2005): Landmark review connecting DNA damage response defects to neurodegeneration, establishing DNA-PKcs as a key player in neuronal survival.

3. Mathew et al. (2007): First demonstration of DNA-PKcs deficiency in AD brains, showing reduced kinase activity and impaired DNA repair capacity.

4. Khurana et al. (2017): Breakthrough discovery that DNA-PKcs directly phosphorylates tau at AD-relevant sites, linking DNA damage to tau pathology.

5. Zhang et al. (2023): Confirmed DNA-PKcs-mediated tau phosphorylation in human AD brains, supporting therapeutic targeting.

Ongoing Research Areas

• DNA-PKcs inhibitors for AD treatment

• Genetic manipulation of DNA-PKcs in neurodegeneration models

• Biomarker development for DNA-PKcs activity

• CNS delivery of DNA-PKcs-targeted compounds

• Combination therapies targeting multiple pathways

Comparison with ATM and Related Kinases

Both ATM and DNA-PKcs are PI3/PI4-related kinases involved in DNA damage response. ATM primarily functions as a checkpoint kinase, while DNA-PKcs is the central effector of NHEJ. In neurons, DNA-PKcs is particularly important due to their reliance on NHEJ for DNA repair.

Summary

DNA-dependent protein kinase catalytic subunit (DNA-PKcs) is a 469 kDa serine/threonine kinase that plays essential roles in DNA double-strand break repair through the non-homologous end joining pathway. Originally characterized for its DNA repair functions, DNA-PKcs has emerged as a key player in neurodegenerative diseases, particularly Alzheimer’s disease where it directly phosphorylates tau protein at disease-relevant sites. In Parkinson’s disease, DNA-PKcs contributes to dopaminergic neuron vulnerability through DNA damage accumulation and mitochondrial dysfunction.

The therapeutic targeting of DNA-PKcs in neurodegeneration presents a complex challenge due to its dual role in both promoting pathology (through tau phosphorylation) and maintaining neuronal survival (through DNA repair). Ongoing research focuses on developing brain-penetrant DNA-PKcs inhibitors that can modulate pathological signaling while preserving sufficient DNA repair capacity. Understanding the precise context-dependent roles of DNA-PKcs will be critical for developing effective neuroprotective strategies.

Cross-References

• PRKDC Gene — Gene encoding DNA-PKcs

• DNA Repair Pathways — Related mechanism

• Alzheimer’s Disease — Disease association

• Parkinson’s Disease

• Tau Protein — DNA-PKcs phosphorylation substrate

• Amyloid-Beta Protein — AD pathology

• Ku70/Ku80 — DNA-PKcs complex partners

• DNA Damage Response — Related pathway

External Links

• UniProt P78527

• AlphaFold Structure

• GeneCards PRKDC

• OMIM 255761

• NCBI Gene: 5597